Eli Lilly and Company has seen a notable shift in relative strength, moving lower within the SIA S&P 100 Index Report as technical conditions weaken. A bearish Point & Figure signal alongside a break of prior support suggests momentum may be fading after a period of strength. With the Drugs sector also softening within the SIA Sector Report, LLY’s relative positioning may continue to face pressure near term.